Literature DB >> 9675463

Risk factors for death among cancer patients with fungemia.

M Nucci1, M I Silveira, N Spector, F Silveira, E Velasco, T Akiti, G Barreiros, A Derossi, A L Colombo, W Pulcheri.   

Abstract

In order to identify prognostic factors for death among cancer patients with fungemia, an 18-month survey of fungemia in patients with cancer was undertaken in three hospitals in Rio de Janeiro. For the assessment of risk factors for death, the following variables were analyzed: age; gender; underlying cancer; last treatment for the underlying disease; previous surgery; use of antibiotics, antifungal agents, steroids, or total parenteral nutrition; use of a central venous catheter; chemotherapy; radiotherapy; presence and duration of neutropenia; etiologic agent of the fungemia; treatment of the fungemia; clinical manifestations; and performance status (Karnofsky score) on the day of the positive blood culture. In multivariate analysis, the variables associated with an increased risk for death were older age, persistent neutropenia, and low performance status. Identifying risk factors for death may help to define a group-risk patients for whom new therapeutic options should be tried.

Entities:  

Mesh:

Year:  1998        PMID: 9675463     DOI: 10.1086/514609

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  13 in total

1.  Therapeutic Approach to Candida Sepsis.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-08       Impact factor: 3.725

2.  Phialemonium fungemia: two documented nosocomial cases.

Authors:  J Guarro; M Nucci; T Akiti; J Gené; J Cano; M D Barreiro; C Aguilar
Journal:  J Clin Microbiol       Date:  1999-08       Impact factor: 5.948

3.  Prospective evaluation of the epidemiology, microbiology, and outcome of bloodstream infections in adult surgical cancer patients.

Authors:  E Velasco; M Soares; R Byington; C A S Martins; M Schirmer; L M C Dias; V M S Gonçalves
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-07-28       Impact factor: 3.267

4.  Effect of antifungal therapy timing on mortality in cancer patients with candidemia.

Authors:  Ying Taur; Nina Cohen; Sarah Dubnow; Alla Paskovaty; Susan K Seo
Journal:  Antimicrob Agents Chemother       Date:  2009-11-02       Impact factor: 5.191

5.  A prospective cohort study evaluating the prognostic impact of clinical characteristics and comorbid conditions of hospitalized adult and pediatric cancer patients with candidemia.

Authors:  E Velasco; R Bigni
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-06-12       Impact factor: 3.267

6.  Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Peter G Pappas; Carol A Kauffman; David R Andes; Cornelius J Clancy; Kieren A Marr; Luis Ostrosky-Zeichner; Annette C Reboli; Mindy G Schuster; Jose A Vazquez; Thomas J Walsh; Theoklis E Zaoutis; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2015-12-16       Impact factor: 9.079

7.  Model of Chemotherapy-associated Mucositis and Oral Opportunistic Infections.

Authors:  Takanori Sobue; Martinna Bertolini; Angela Thompson; Anna Dongari-Bagtzoglou
Journal:  Bio Protoc       Date:  2019-11-05

8.  Fluconazole for empiric antifungal therapy in cancer patients with fever and neutropenia.

Authors:  Donghui T Yu; Diane L Seger; Josh F Peterson; Ritesh N Kumar; David W Bates
Journal:  BMC Infect Dis       Date:  2006-12-05       Impact factor: 3.090

9.  Revisiting Infectious Complications Following Total Parenteral Nutrition Use During Hematopoietic Stem Cell Transplantation.

Authors:  Halina Rubin; Jayesh Mehta; Jessica L Fong; Deborah Greenberg; Solomiya GrusChak; Steven Trifilio
Journal:  J Adv Pract Oncol       Date:  2020-09-01

10.  Candida isolates in tertiary hospitals in northeastern Brazil.

Authors:  Sylvia Lemos Hinrichsen; Erica Falcão; Tatiana Aguiar Santos Vilella; Leandro Rêgo; Conceição Lira; Luciano Almeida; Mízia Martins; Carmem Araújo; Marcelo Duarte; Geraldo Lopes
Journal:  Braz J Microbiol       Date:  2009-06-01       Impact factor: 2.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.